or those who cannot meet 60% of the daily requirement by postoperative day 6 should be given individualized nutritional support. 2 For all postoperative patients who have a functioning gastrointestinal (GI) tract but cannot tolerate oral intake, standard EN is generally recommended because it is less expensive, safer, and more physiological to maintain the barrier function of the intestines than any artificial nutritional support. Meta-analysis reports suggest that EN is conducive to a lower infection rate and a shorter hospital stay than parenteral nutrition (PN) in GI surgical patients. 3, 4 However, if patients cannot receive adequate EN as a result of GI incompetency such as ileus, bowel ischemia, severe GI bleeding, or critical illness with poor enteral tolerance, then PN is required. In our previous study, we found that compared with patients without nutritional support, morbidity and mortality of malnourished gastrectomy patients with peri-or postoperative total parenteral nutrition (TPN) significantly decreased. 5 To reduce postoperative complications and achieve immune homeostasis through regulating cell function, physicians introduce enteral or parenteral formulas supplemented with nutrients having immunomodulatory properties. This type of supplementation is termed immunonutrition. Commonly in the formulas, some of the immunonutrients, such as glutamine (GLN), arginine (Arg), n-3 polyunsaturated fatty acids (PUFA), and nucleotides, are supplemented alone or in combination. Previous meta-analyses found that immunonutrition reduces overall postoperative complications and shortens hospital stay in adult patients with major abdominal surgery.
6,7
According to a meta-analysis specifically for total gastrectomy patients with GC, enteral immunonutrition improves cellular immunity, modulates inflammatory response, and reduces postoperative complications. 8 Previous studies using immunonutritional regimens were conducted using either one specific nutrient or in different combinations of nutritional components. In the present review, we explored and summarized the evidence obtained from clinical trials and animal studies supporting the role of immunonutrients supplemented enterally or parenterally in total or subtotal gastrectomy. This review also describes the possible molecular mechanisms underlying the protective action of these immunonutrients, which may contribute to the therapeutic approaches to improve postoperative outcomes of gastrectomy.
| N UTRITI ONAL SUPP ORT IN PATIENTS WITH G C RECEIVING G A S TREC TOMY

| Effects of specific nutrient combination on gastrectomy
Although immunonutrition has agreeably favorable effects, different time points of intervention may influence the outcomes after gastrectomy. In a previous study, an enteral immune-enhancing formula enriched with Arg, n-3 fatty acids (FA), and ribonucleic acid (RNA), named "Impact (Novartis Nutrition, Bern, Switzerland)," was given to patients with GC in two distinct time periods; then, the potential benefits of perioperative versus postoperative treatments on host defense and protein metabolism were evaluated. Compared with postoperative dosage, perioperative supplementation of immunonutrition had more metabolic advantages in modulating postoperative immune and inflammatory responses in gastrectomy patients with GC. 9 However, early postoperative EN with Impact supplementation increased collagen synthesis, thereby promoting wound healing 10 and improving the clinical and immunological outcomes of these patients. 11 Okamoto et al 12 found that preoperative EN with Impact supplementation maintained CD4 + T-cell levels, shortened the duration of systemic inflammatory response syndrome, and decreased the incidence of postoperative infectious complications in patients with GC. In another study, Impact was included in a normal diet for GC. 19 A meta-analysis concluded that among the immunonutrients used for enteral immunonutrition, namely, Arg, GLN, n-3 FA, and RNA, RNA and n-3 FA are the most effective in reducing infectious complications and length of hospital stay in patients with GC suffering from gastrectomy. 20 In a rodent sarcopenia model induced by total gastrectomy, Haba et al 21 investigated the effect of oral branched-chain amino acids (BCAA) and/or GLN supplementation on skeletal muscle atrophy after surgery. They found that combined use of BCAA and GLN was more effective in inhibiting muscle atrophy than providing BCAA or GLN alone. Considering that several immunonutrients are combined in enteral immunonutrition formulas, the influence of each immunonutrient on gastrectomy cannot be confirmed. Therefore, we summarized the studies that used the most commonly used immunonutrients, and we describe the roles of these immunonutrients on gastrectomy. highly balanced T-cell subsets during metabolic stress.
| Effects of FA on gastrectomy
24,25
A randomized clinical trial compared n-3 FA-supplemented EN with a standard formula for 7 days before and after operation in patients with subtotal esophagectomy or total gastrectomy.
Consequently, perioperative enteral immunonutrition with n-3
FA did not affect the clinical outcomes of esophagogastrectomy patients. 26 Moreover, Ida et al investigated the addition of EPAenriched nutrition to a standard diet in patients with GC undergoing total gastrectomy. Oral supplementation with 2.2 g EPA was provided for 7 preoperative days and 21 postoperative days. Compared with the standard diet, an EPA-enriched oral diet did not influence surgical morbidity and body weight loss after total gastrectomy.
27
With regard to PN, Makay et al 28 evaluated the effect of postoperative n-3 FA dosage on cellular hypoperfusion associated with major gastric surgery. They found that PN with n-3 FA supplementation did not have a significant effect on lactate clearance and cellular hypoperfusion after major gastrectomy. In a prospective, randomized controlled trial, patients with GC were treated with n-3 FA-rich fish oil fat emulsion or received soybean oil by PN after surgery.
Although mean plasma lactate concentration in patients with n-3 FA was higher, the difference was not statistically significant. 
| Effects of GLN on gastrectomy
Glutamine is the most abundant amino acid in mammalian plasma and intracellular pools. Many important physiological functions depend directly or indirectly on GLN metabolism. GLN is a shuttle for nitrogen transport, an antioxidant precursor, a source of carbon and nitrogen, and an energy source for rapidly proliferating cells. As for animal studies, rats were infused with GLN-containing PN before and after gastrectomy to investigate the efficacy of GLN on surgery. As a result, TPN supplemented with GLN improved nitrogen balance and enhanced abdominal macrophage phagocytic activity in rats with partial gastrectomy. 45 In a previous study, we gave GLN parenterally to investigate the role of GLN on cellular adhesion molecule and inflammatory cell recruitment in rats with total gastrectomy. We found that GLN-enriched PN attenuated leukocyte integrin expression and elicited a more rapid immune response to injury after gastrectomy. 46 
| Effects of Arg on gastrectomy
Arginine is a nonessential amino acid that serves as the precursor of various metabolites, such as nitric oxide (NO), citrulline, creatine, ornithine, urea, and polyamines. 47 Arg stimulates anabolic hormone release and improves nitrogen balance. 48 It also shows immunoregulatory characteristics 49 and can attenuate an inflammatory response in stressful conditions. 50 Conversely, Arg deficiency or unavailability inhibits T-lymphocyte proliferation, resulting in diverse impairments in the immune system and response. 51 The resulting immune
TA B L E 1 Studies on enteral immunonutrition in gastrectomy
Reference
Immunonutrients Time point Outcomes
Braga et al BCAA and GLN Postoperation Inhibits muscle atrophy after surgery dysfunction is associated with an increased risk of infection in critically ill patients. 52 Arg is considered a conditionally essential amino acid for catabolic patients. 53, 54 However, Arg supplementation remains controversial, especially for patients with sepsis. Although meta-analysis studies found that Arg supplementation has no effect on infectious complications and may deteriorate outcomes in critically ill patients, Arg supplementation is associated with reduced infectious complication rates and a short length of hospital stay with no adverse effects on mortality in patients receiving elective surgery. 55 Recently, in human studies, Arg has been found to decrease clinical infections, postoperative hospital stay, intra-abdominal abscess and anastomotic leak, and mortality. 53, 56 A review reported that the dosage of Arg available in commercial formulations is nontoxic and that parenteral delivery of Arg is also safe at clinical levels.
Therefore, Arg should be considered for inclusion in immunonutrient combinations in patients who have suffered trauma and those in acute surgical settings. Tables 1 and 2 .
| CON CLUS ION
In the present review, although we narrowed down the populations of patients to gastrectomy, the findings among the studies have inconsistencies. The fundamental and nutritional status of the recruited patients, the stage and severity of GC, the methods of operation, the intervention dosage, and the time of measuring outcomes are all confounding variables that make each clinical trial different from others. Meanwhile, data derived from animal studies cannot be extrapolated to humans, and studies with a small sample size may have a low statistical power that requires cautious interpretation.
However, most studies reviewed in this report suggested that immunonutrients that are provided either alone or in combination have favorable effects in improving patient outcomes, except that the exclusive use of arginine is rare and needs to be confirmed in gastrectomy patients with GC. Conventional therapy in combination with immunonutrition pre-and/or postoperatively may be an important strategy to achieve favorable synergistic effects in the management of GC patients.
D I SCLOS U R E
Conflicts of Interest: Authors declare no conflicts of interest for this article.
O RCI D
Jin-Ming Wu https://orcid.org/0000-0002-1821-239X
Ming-Tsan Lin https://orcid.org/0000-0001-7313-7057
